Sinotherapeutics Inc. (SHA:688247)

China · Delayed Price · Currency is CNY

9.27

-0.12 (-1.28%)

Sep 9, 2026, 4:00 PM EDT

Sinotherapeutics Financials Overview

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	418.12	446.57	511.62	299.87	247.56	315.47
Revenue Growth	-18.53%	-12.72%	70.61%	21.13%	-21.53%	-1.16%
Gross Profit	149.43	160.59	265.51	166.37	179.12	245.03
Operating Income	15.49	34.62	119.48	44.3	58.21	95.1
Net Income	31.6	47.48	127.7	61.07	92.93	134.92
Earnings Per Share	0.08	0.11	0.28	0.13	0.22	0.33
EPS Growth	-70.77%	-60.71%	115.39%	-40.91%	-33.33%	10.00%

Revenue by Geography

Fiscal Year	FY 2025
Period Ending	Dec '25 Dec 31, 2025
China	316.39
Overseas	129.66
Total	446.05

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Investments	813.72	746.45	733.53	749	807.23	511.66
Total Debt	0.04	0.02	0.01	0.09	1.52	4.44
Net Cash (Debt)	813.68	746.43	733.53	748.92	805.71	507.22
Net Cash Growth	9.47%	1.76%	-2.05%	-7.05%	58.85%	16.82%
Net Cash Per Share	1.96	1.73	1.61	1.59	1.91	1.24

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Cash Flow	131.39	95.33	130.23	12.96	73.18	145.77
Capital Expenditures	-29.8	-41.56	-94.93	-38.96	-176.34	-16.01
Free Cash Flow	101.59	53.77	35.3	-26	-103.15	129.77
Free Cash Flow Growth	711.19%	52.32%	-	-	-	-24.42%

Margins

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Gross Margin	35.74%	35.96%	51.90%	55.48%	72.35%	77.67%
Operating Margin	3.71%	7.75%	23.35%	14.77%	23.51%	30.14%
Pretax Margin	8.24%	11.94%	27.77%	22.01%	39.37%	47.24%
Profit Margin	7.56%	10.63%	24.96%	20.37%	37.54%	42.77%
FCF Margin	24.30%	12.04%	6.90%	-8.67%	-41.67%	41.13%

Dividends

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep '26 Sep 10, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Dividend Per Share	0.035	0.035	0.062	0.041	0.062
Dividend Per Share Growth	-43.55%	-43.55%	51.22%	-33.87%	-
Dividend Yield	0.38%	0.36%	0.62%	0.38%	0.38%

Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 10, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
PE Ratio	122.01	91.73	35.37	81.50	81.71	-
P/FCF Ratio	40.97	81.00	127.97	-	-	-
PS Ratio	9.95	9.75	8.83	16.60	30.67	-